Roivant Sciences (ROIV) Q2 2025 earnings summary

Executive summary

• Reported strong 52-week phase II data for brepocitinib in NIU and positive results for batoclimab in Graves' disease, with sustained efficacy and favorable safety profiles; multiple late-stage and registrational trials ongoing or planned.

• Closed the Dermavant transaction with Organon, receiving $184M in cash, transferring $336M in debt, and maintaining upside from VTAMA; potential for up to $950M in milestones and tiered royalties.

• Significant share repurchases totaling $754M through September 30, 2024, including the Sumitomo buyback and open market transactions.

• Ended the quarter with $5.4B in consolidated cash, cash equivalents, and marketable securities, and no debt following the Dermavant transaction.

• Focused on clinical execution with multiple ongoing and upcoming pivotal trials across key assets, and ongoing business development negotiations for new in-licensing opportunities.

Financial highlights

• R&D expenses were $143.1M (adjusted non-GAAP $132M), up year-over-year due to higher program-specific and personnel costs.

• G&A expenses were $202.9M (adjusted non-GAAP $142M), mainly due to one-time executive and employee retention awards and higher share-based compensation.

• Loss from continuing operations was $237M (adjusted non-GAAP $219M); net loss attributable to Roivant was $230.2M, or $0.31 per share.

• Revenue for the quarter was $4.5M, up from $3.6M year-over-year, but remains immaterial.

• Interest income increased to $69.8M, reflecting higher cash balances and interest rates.

Outlook and guidance

• Multiple pivotal and registrational trials expected to initiate or report data in 2025, including for IMVT-1402, batoclimab, and brepocitinib.

• Anticipates $75M milestone payment from Organon upon FDA approval of VTAMA in atopic dermatitis, with a target action date in Q1 2025.

• Expects R&D and G&A expenses to decrease in coming quarters due to the Dermavant divestiture and one-time expenses being behind.

• Ongoing commitment to prudent capital deployment and potential for additional shareholder returns.

• Ongoing business development activities and negotiations for new licensing opportunities in a favorable environment.